* Tend to be slower to publicize treatment problems than breakthroughs;
* Tend not to openly question drug prices;
* Tend to encourage patients to stay on their medications and offer programs to help patients stay on their medicationmedications, and push insurers to pay for it;
* Funding from drug companies to the organization usually comes from the drug makers' marketing or sales divisions, not charity offices;
* Fail to adequately discuss, or minimize discussion of adverse drug side effects of drugs like brain damage or suicide;